Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 395 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 395 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.69, for a total value of $27,527.55. Following the transaction, the senior vice president directly owned 16,899 shares of the company’s stock, valued at $1,177,691.31. This represents a 2.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.72, for a total value of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $68.86 on Tuesday. Oruka Therapeutics, Inc. has a twelve month low of $10.77 and a twelve month high of $91.00. The stock has a market capitalization of $4.15 billion, a PE ratio of -35.49 and a beta of -0.25. The stock has a 50-day simple moving average of $63.71 and a 200 day simple moving average of $44.31.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Oruka Therapeutics

Large investors have recently added to or reduced their stakes in the company. Fairmount Funds Management LLC raised its holdings in shares of Oruka Therapeutics by 9.9% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after buying an additional 333,340 shares in the last quarter. Secure Asset Management LLC acquired a new position in shares of Oruka Therapeutics in the 4th quarter worth approximately $2,475,000. Avoro Capital Advisors LLC acquired a new position in shares of Oruka Therapeutics in the 3rd quarter worth approximately $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Oruka Therapeutics in the 3rd quarter worth approximately $296,000. Finally, Commodore Capital LP raised its holdings in shares of Oruka Therapeutics by 23.5% in the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock worth $33,711,000 after buying an additional 333,340 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Analysts Set New Price Targets

ORKA has been the subject of several research analyst reports. Barclays boosted their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, April 27th. Wedbush set a $165.00 price target on Oruka Therapeutics in a report on Monday, April 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a report on Wednesday, June 3rd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Oruka Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $131.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.